scholarly journals CARDIAC SARCOIDOSIS PRESENTING WITH VENTRICULAR ARRHYTHMIAS

2020 ◽  
Vol 53 (1) ◽  
Author(s):  
Muhammad Faisal Khanzada ◽  
Zubair Mumtaz ◽  
Abdul Mueed ◽  
Sajid Ali Shaikh ◽  
Syed Haseeb Raza Naqvi ◽  
...  
Heart Rhythm ◽  
2021 ◽  
Vol 18 (8) ◽  
pp. S170
Author(s):  
Konstantinos N. Aronis ◽  
David Robert Okada ◽  
Eric Xie ◽  
Usama A. Daimee ◽  
Adityo Prakosa ◽  
...  

EP Europace ◽  
2012 ◽  
Vol 15 (3) ◽  
pp. 347-354 ◽  
Author(s):  
Jordana Kron ◽  
William Sauer ◽  
Joseph Schuller ◽  
Frank Bogun ◽  
Thomas Crawford ◽  
...  

2021 ◽  
Vol 42 (Supplement_1) ◽  
Author(s):  
Q Dai ◽  
B Bose ◽  
P Li ◽  
B Liu ◽  
L Jin ◽  
...  

Abstract Background Sarcoidosis is a systemic granulomatous disease with cardiac involvement reported in 20–27% of patients [1]. Cardiac sarcoidosis (CS) can lead to atrial or ventricular arrhythmias, various conduction system disorders, heart failure or sudden cardiac death, depending on the location of myocardial involvement [2]. Previous studies have investigated the possible types of CS based on the distribution of myocardial involvement on imaging as well as the role of genetic factors [3,4]. However, there are no studies describing the clinical heterogeneity of CS patients. Purpose In order to determine if clinical clusters exist in CS, we carried out a latent class analysis (LCA) to explore potential phenotypes in a large sample of CS patients from the National Inpatient Sample (NIS). Methods We identified 848 patients with a diagnosis of CS from the NIS in 2016–2018. A LCA was performed based on comorbidities. Utilizing the Bayesian information criterion and Akaike's information criterion we divided our study population into 3 cohorts. We subsequently applied the LCA model for our study population to fit each patient into one of the 3 cohorts. Finally, we compared the clinical outcomes among the 3 groups. Results Following LCA, patients in cohort 3 were strongly associated with a cardiometabolic syndrome profile with the highest prevalence of congestive heart failure (CHF, 95.1%), chronic kidney disease (CKD, 69.7%), diabetes mellitus (68.9%), hyperlipidemia (52.5%) and obesity (45.1%). Patients in cohort 2 had an intermediate prevalence of cardiometabolic syndrome with a universal diagnosis of hypertension (100%) but with the lowest number of CHF (32.5%) patients and none with CKD. Finally, patients in cohort 1 had the least comorbidities in comparison to the other groups but there was a higher prevalence of CHF (71.7%). There was no significant difference in mortality among the 3 groups, but acute respiratory failure was the highest in cohort 3. However, ventricular arrhythmias were more prevalent in cohort 1 patients (Table). Conclusion We identified 3 different types of CS based on their clinical phenotype. The clinical outcomes varied among the cohorts with ventricular arrhythmias being the most prevalent in patients with the least cardiometabolic comorbidities. FUNDunding Acknowledgement Type of funding sources: None.


CHEST Journal ◽  
2020 ◽  
Vol 158 (4) ◽  
pp. A131-A132
Author(s):  
Matthew Bocchese ◽  
David Rosenthal ◽  
Abdullah Haddad ◽  
Benjamin Rosenfeld ◽  
Crystal Chen ◽  
...  

2011 ◽  
Vol 16 (2) ◽  
pp. 140-147 ◽  
Author(s):  
Kenji Yodogawa ◽  
Yoshihiko Seino ◽  
Toshihiko Ohara ◽  
Hideo Takayama ◽  
Takao Katoh ◽  
...  

2017 ◽  
Vol 38 (04) ◽  
pp. 477-498 ◽  
Author(s):  
David Sayah ◽  
Jason Bradfield ◽  
John Moriarty ◽  
John Belperio ◽  
Joseph Lynch

AbstractClinically evident sarcoidosis involving the heart has been noted in at least 2 to 7% of patients with sarcoidosis, but occult involvement is much higher (> 20%). Cardiac sarcoidosis is often not recognized antemortem, as sudden death may be the presenting feature. Cardiac involvement may occur at any point during the course of sarcoidosis and may occur in the absence of pulmonary or systemic involvement. Sarcoidosis can involve any part of the heart, with protean manifestations. Prognosis of cardiac sarcoidosis is related to the extent and site(s) of involvement. Most deaths due to cardiac sarcoidosis are due to arrhythmias or conduction defects, but granulomatous infiltration of the myocardium may be lethal. The definitive diagnosis of isolated cardiac sarcoidosis is difficult. The yield of endomyocardial biopsies is low; treatment of cardiac sarcoidosis is often warranted even in the absence of histologic proof. Radionuclide scans are integral to the diagnosis. Currently, 18F-fluorodeoxyglucose–positron emission tomography/computed tomography and gadolinium-enhanced magnetic resonance imaging scans are the key imaging modalities to diagnose cardiac sarcoidosis. The prognosis of cardiac sarcoidosis is variable, but mortality rates of untreated cardiac sarcoidosis are high. Although randomized therapeutic trials have not been done, corticosteroids (alone or combined with additional immunosuppressive medications) remain the mainstay of treatment. Because of the potential for sudden cardiac death, implantable cardioverter defibrillators should be placed in any patient with cardiac sarcoidosis and serious ventricular arrhythmias or heart block, and should be considered for cardiomyopathy. Cardiac transplantation is a viable option for patients with end-stage cardiac sarcoidosis refractory to medical therapy.


2020 ◽  
Vol 9 (4) ◽  
pp. 182-188
Author(s):  
Nisha Gilotra ◽  
David Okada ◽  
Apurva Sharma ◽  
Jonathan Chrispin

Sarcoidosis is an inflammatory granulomatous disease that can affect any organ. Up to one-quarter of patients with systemic sarcoidosis may have evidence of cardiac involvement. The clinical manifestations of cardiac sarcoidosis (CS) include heart block, atrial arrhythmias, ventricular arrhythmias and heart failure. The diagnosis of CS can be challenging given the patchy infiltration of the myocardium but, with the increased availability of advanced cardiac imaging, more cases of CS are being identified. Immunosuppression with corticosteroids remains the standard therapy for the acute inflammatory phase of CS, but there is an evolving role of steroid-sparing agents. In this article, the authors provide an update on the diagnosis of CS, including the role of imaging; review the clinical manifestations of CS, namely heart block, atrial and ventricular arrhythmias and heart failure; discuss updated management strategies, including immunosuppression, electrophysiological and heart failure therapies; and identify the current gaps in knowledge and future directions for cardiac sarcoidosis.


Sign in / Sign up

Export Citation Format

Share Document